The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Hirayama, Alexandre V.; Gauthier, Jordan; Hay, Kevin A.; Voutsinas, Jenna M.; Wu, Qian; Gooley, Ted; Li, Daniel; Cherian, Sindhu; Chen, Xueyan; Pender, Barbara S.; Hawkins, Reed M.; Vakil, Aesha; Steinmetz, Rachel N.; Acharya, Utkarsh H.; Cassaday, Ryan D.; Chapuis, Aude G.; Dhawale, Tejaswini M.; Hendrie, Paul C.; Kiem, Hans-Peter; Lynch, Ryan C.; Ramos, Jorge; Shadman, Mazyar; Till, Brian G.; Riddell, Stanley R.; Maloney, David G.; Turtle, Cameron J.

doi:10.1182/blood-2018-11-887067

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not been identified. We report multivariable analyses of factors affecting response and progression-free survival (PFS) in patie…